ClinicalTrials.gg
RecruitingNCT06668623Updated Feb 14, 2025

Effect of Reiki on Neuropathic Pain Severity and Sleep Quality in Patients with Diabetic Neuropathy

An interventional study of Reiki Group and Sham Reiki Group in Diabetic Neuropathy, sponsored by TC Erciyes University. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by TC Erciyes University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Diabetic Neuropathies with a site in Turkey — 6 open to participants now, 7 under way, none of them phase 3. Diabetic Neuropathies · Turkey.

Planned enrollment
8th of 20
60 · median 49
Started
2024
with 3 others
No phase
18 of 28
4 open now
Registered
15th of 28
by date

Among the 28 studies in Diabetic Neuropathies with a site in Turkey, this one is the 8th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2024, is one of 18 with no phase, and was the 15th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

6 of the 28 studies in Diabetic Neuropathies with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Diabetic Neuropathies with a site in Turkey, or all of them as a file.
02

Study summary

The study is planned to be conducted in a mixed research design with quantitative and qualitative types. The quantitative phase of the study was planned as a single-blind, randomized controlled study with Reiki group, Sham Reiki group and control group designs in order to examine the effect of second-level (remote application) Reiki applied to patients with diabetic neuropathy for 20 minutes a day for four days on pain intensity, neuropathic pain intensity (DN4 Questionnaire) total scores and sleep quality. The qualitative study will be conducted with 4 people from the Reiki and Sham Reiki groups, a total of 8 patients, one week after the application, using the individual in-depth interview method and a semi-structured questionnaire.

Read the detailed description

Research hypotheses;

H01: Second-level Reiki applied to patients with diabetic neuropathy for 20 minutes once a day for 4 days has no effect on reducing pain intensity.

H11: Second-level Reiki applied to patients with diabetic neuropathy for 20 minutes once a day for 4 days has an effect on reducing pain intensity.

H02: Second-level Reiki applied to patients with diabetic neuropathy for 20 minutes once a day for 4 days has no effect on reducing neuropathic pain intensity.

H12: Second-level Reiki applied to patients with diabetic neuropathy for 20 minutes once a day for 4 days has an effect on reducing neuropathic pain intensity.

H03: Second-level Reiki applied to patients with diabetic neuropathy for 20 minutes once a day for 4 days has no effect on sleep quality.

H13: Second-level Reiki applied to patients with diabetic neuropathy for 20 minutes once a day for 4 days has an effect on sleep quality.

Reiki/Sham Reiki Application Protocol After the assignment of patients with diabetic neuropathy to the groups by lot, the Reiki group will be applied remotely by a researcher who has received second-level training, and the Sham Reiki group will be applied remotely by a nurse who is not a Reiki practitioner trained by the researcher and has not received any training before, in accordance with the application protocol.

Research Groups Intervention Group-1 A 20-minute remote Reiki application will be applied once a day for four days by a researcher who has received second-level training. No changes will be made to the standard treatment plan of the patients during the application.

Intervention Group-2 A 20-minute remote Sham Reiki application will be applied once a day for four days by a nurse who has not received Reiki training and has not been initiated. No changes will be made to the standard treatment plan of the patients during the application.

Control Group No application will be applied to the patients for four weeks. Individuals will continue to receive their normal treatments.

03

Conditions studied

  • Diabetic Neuropathy

Keywords

  • Diabetic Neuropathy
  • Pain
  • Sleep Quality
  • Reiki
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years of age
  • No communication problems
  • Communicating in Turkish
  • No diagnosis of mental illness
  • Willingness to participate in the study
  • Being competent enough to answer forms and surveys
  • VAS pain intensity 3 and above
  • 4 Question Neuropathic Pain score 4 and above
  • Not having received Reiki treatment

Exclusion criteria

Exclusion Criteria:

  • Receiving a different illness and treatment during the therapy process
  • Leaving Reiki practice
  • Psychiatric illness
  • Becoming a Reiki practitioner or instructor
  • Cerebrovascular disease
  • Receiving Reiki practice
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Reiki Group

    Remote Reiki application will be performed once a day for 20 minutes for four days by a researcher who has received second-level training.

    Other: Reiki Group

  • Sham comparator
    Sham Reiki Group

    In the placebo group, the Sham Reiki group will receive remote Reiki application in accordance with the application protocol by a nurse who is not a Reiki practitioner trained by the researcher and has not received any previous training.

    Other: Sham Reiki Group

  • No intervention
    control group

    For four weeks, patients will not receive any treatment. Individuals will continue to receive their normal treatments.

Interventions

  • OtherReiki Group

    Remote Reiki application will be performed once a day for 20 minutes for four days by a researcher who has received second level training. No changes will be made to the standard treatment plan of the patients during the application.

  • OtherSham Reiki Group

    In the placebo group, the Sham Reiki group will receive remote Reiki application in accordance with the application protocol by a nurse who is not a Reiki practitioner trained by the researcher and has not received any previous training.

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale(VAS)

    The value of "0 points" in the scale, which indicates the absence of pain, indicates a good condition, and the maximum value, "10 points", indicates a bad condition with unbearable pain intensity.

    Time frame: Pre-test data will be collected before starting the study and post-test data will be collected 1 week later.

Secondary outcomes

  1. McGill Pain Scale - Short Form

    The scale form provides information on the sensory intensity, size and perceived effects of pain. In this respect, the scale consists of three dimensions. The first dimension includes 15 items that define the quality of pain. 11 of the items are sensory and 4 determine the perceptual dimension of pain. The intensity of pain is indicated in the items by grading between 0-3 (0=none, 1=mild, 2=moderate, 3=excessive). In the first dimension, the perceptual pain score is evaluated between 0-12, the sensory pain score is evaluated between 0-33 and the total pain score is evaluated between 0-45. An increase in the total score indicates an increase in the pain level. In the second dimension, the intensity of pain felt by the individual is determined by five expressions ranging from "mild pain" to "unbearable pain". In the third dimension, the individual's instant intensity is compared visually. The scale is listed in 0-5 points options. Minimum ''0=point, no pain; Indicates good condition.

    Time frame: Pre-test data will be collected before starting the study and post-test data will be collected 1 week later.

Other outcomes

  1. 4 Question Neuropathic Pain Questionnaire (DN4)

    The first two questions are based on interviews with the patient; The first question is about the definition of pain (tingling, burning, cold), and the second question is; It is related to paresthesia and dysesthesia (numbness, prickling, tingling and itching) in the painful area. The third question examines sensory disturbances (needling, touch and hypoesthesia) in the area where the pain is localized, and the fourth question; It determines whether friction causes an increase in the presence and severity of pain. Each question is scored as "yes answer = 1 point" or "no answer = 0 point". A minimum score of 4 points and above indicates neuropathic pain. Indicates a bad situation. A maximum score of 10 is taken from the scale. This indicates that the pain is severe and worse.

    Time frame: Pre-test data will be collected before starting the study and post-test data will be collected 1 week later.

  2. Pittsburgh Uyku Kalitesi Endeksi PUKI

    Each item is evaluated between 0-3 points. The scale consists of 7 subcomponents that evaluate objective sleep quality (component 1), sleep latency (component 2), sleep duration (component 3), sleep habits, sleep disorders, sleeping pill use (component 5, component 6) and loss of daytime functionality. The sum of these components is the PSQI score. It indicates that sleep disturbance is severe in at least two of the 7 components or moderate in three component areas. A minimum score of 0-5 on the scale indicates that sleep quality is good. 5 points and above indicate that sleep quality is poor. Maximum scale total score It is 21 points.

    Time frame: Pre-test data will be collected before starting the study and post-test data will be collected 1 week later.

07

Study locations

1 of 1 sites recruiting
  • Kayseri City Hospital
    Kayseri, Kocasinan 38010, Turkey
    Recruiting
    • Fatma Gönül BURKEV · Contact05071549118
    • Fatma Gönül BURKEV, Phd.Student · Contact
    • Sultan TAŞCI, Prof.Dr. · Contact
    • Ali ÇETİNKAYA, Doç. Dr. · Contact
08

References and documents

Individual participant data

Plan to share: No — Once the study is completed, its results will be shared with other researchers once the study data is published.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2025, 6 months after the start.

Of 138 non-industry interventional studies with no phase under Diabetic Neuropathies, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 6 months is below that.

Counting every sponsor, half of 153 studies reached it within 11 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2024
First posted
Oct 31, 2024
StartActual
Nov 1, 2024
Primary completionEst.
May 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06668623
Responsible party
Fatma Gonul Burkev (Principal Investigator, Kayseri City Hospital) — Principal investigator
First posted
Oct 31, 2024
Start date
Nov 1, 2024
Primary completion
May 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Feb 14, 2025

Study contacts

Fatma G. BURKEV, PhD student
Contact
fatmaburkev@gmail.com
+90 0352 315 77 00

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion